Access Oncology Inc., Gem Pharm deal

Access licensed from Gem GPX-100 and GPX-150, 2 non-cardiotoxic analogs of doxorubicin, to treat cancer. Gem will receive upfront payments and milestones totaling up to $33 million, plus royalties. Ac...